ALGS

Rating neutralTentativeAI Memo

Aligos Therapeutics

As of 2026-07-31/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Second B-SUPREME interim analysis • 2026-10-29

Base target: $5 / p=50% prob

Biggest risk

The company remains blinded to efficacy data, the stock is a low-coverage small-cap biotech, and the principal asset remains a binary Phase 2 program. A weak interim signal, delay, additional dilution, or inability to extend the runway could drive substantial downside.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The first interim analysis avoided futility, the DSMB recommended expanding the HBeAg- cohort, FDA Fast Track designation was granted, and the $25 million upfront payment reduces near-term financing pressure. A favorable H2 2026 interim update could materially re-rate the shares.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-31

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

China-license cash relief is largely priced in
Pevifoscorvir clinical and Greater China optionality
The first interim analysis avoided futility, the DSMB recommended expanding the HBeAg- cohort, FDA Fast Track designation was granted, and the $25 million upfront payment reduces near-term financing pressure.

BearKey bullets

ASMB and ABUS are contextual HBV comparators rather than clean valuation peers, and analyst-revision coverage is unavailable.
Additional financing or dilution may be required before major 2027 readouts.
Clinical efficacy remains unproven and the H2 2026 interim analysis could disappoint or be delayed.

WatchKey bullets

Second B-SUPREME interim analysis

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $5 (p=50%)

Target spread vs base: +89% / -56%

Scenario probabilities

Bull Target: $9 (p=20%)Base Target: $5 (p=50%)Bear Target: $2 (p=30%)

Commentary

Recent company news is positive because of the $25 million China-license payment and progress toward the next B-SUPREME interim analysis, but the payment-related relief appears largely priced in. The peer set is loose and useful mainly for clinical context, not valuation. No dependable analyst-revision, options, short-interest, employee, or social signal is available; confidence therefore remains limited despite strong primary-source coverage.

As of 2026-07-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

China-license cash relief is largely priced in
Pevifoscorvir clinical and Greater China optionality

Scenarios

Bull Target (Scenario probability)

$9 / p=20% prob

Base Target (Scenario probability)

$5 / p=50% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Analysis 2026-07-31 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-29
Second B-SUPREME interim analysis
A second protocol-defined interim analysis for pevifoscorvir sodium is expected in the second half of 2026. The first interim analysis did not meet futility criteria and led to sample-size expansion, but Aligos remains blinded and efficacy remains incompletely disclosed [#PR-EARNINGS-2026-05-08] [#SEC-8K-2026-05-07].
Prob 65.00% • Move 35.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

China-license cash relief is largely priced in
2026-10-29
The Amoytop deal delivered a $25 million upfront payment, plus potential milestones and royalties, improving near-term financing flexibility. The payment was received on July 6 and the initial repricing appears substantially reflected in the stock [#SEC-8K-2026-04-16] [#PR-2026-07-06].
Prob 100% • Move 12% • Priced-in 90%

Long-term Catalysts

Months to a year

Pevifoscorvir clinical and Greater China optionality
2027-07-31
The Phase 2 B-SUPREME program remains the principal value driver, with topline data planned for 2027; the Greater China license adds potential development, regulatory, commercial milestones, and royalties but remains dependent on clinical and regional execution [#PR-EARNINGS-2026-05-08] [#SEC-10Q-2026-05-07].
Prob 45% • Move 60% • Priced-in 25%

Risks

ASMB and ABUS are contextual HBV comparators rather than clean valuation peers, and analyst-revision coverage is unavailable.
Additional financing or dilution may be required before major 2027 readouts.
Clinical efficacy remains unproven and the H2 2026 interim analysis could disappoint or be delayed.
Greater China milestones and royalties depend on Amoytop development, regulatory, and commercial execution.
The company faces financing and runway risk before major 2027 readouts [#SEC-8K-2026-05-07].

Peers

Symbol	Summary
ASMB	Contextual HBV capsid-assembly-modulator operating peer; useful for mechanism and clinical comparison, but not a clean valuation comparable.
ABUS	Contextual HBV-focused antiviral operating peer with a different modality; useful for competitive and clinical context, not as a standalone valuation anchor.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-31

Loading AI feed…

Symbol

Summary

ASMB

Contextual HBV capsid-assembly-modulator operating peer; useful for mechanism and clinical comparison, but not a clean valuation comparable.

ABUS

Contextual HBV-focused antiviral operating peer with a different modality; useful for competitive and clinical context, not as a standalone valuation anchor.